[Clinical efficacy of endocrinotherapy combined with Shenqi Pills on patients with hormone-sensitive prostate cancer].
Endocrinotherapy combined with Shenqi Pills is safe and effective in HSPC and can reduce the risk of death in HSPC patients, and the earlier the intervention, the longer the overall survival of the patients. In addition, this treatment regimen can increase the PSA response rate, improve patients' quality of life, and reduce the renal-yang deficiency syndrome score without the risk of elevating serum testosterone levels.
Authors
- Xin-Jun Luo
- Biao Wang (ORCID: https://orcid.org/0000-0001-6631-9127)
- Jun Zhou (ORCID: https://orcid.org/0000-0002-3823-7615)
- Fangmeng Fu (ORCID: https://orcid.org/0000-0002-3065-5708)
- Rui‐Song Gao
- Tao Sun (ORCID: https://orcid.org/0000-0001-5931-386X)
- Qun‐Fang Lin
- Yang Yang (ORCID: https://orcid.org/0000-0003-3947-7853)
- Gang Yi
- Xin Yi (ORCID: https://orcid.org/0000-0002-5686-2967)
- Yuhong Xie (ORCID: https://orcid.org/0000-0001-6382-5534)
- Qing Zhou
- Lie Zhang (ORCID: https://orcid.org/0000-0001-9273-8173)
- Qin-Zheng Wang
Institutions
- Hunan University of Traditional Chinese Medicine (CN)
- First Affiliated Hospital of Hunan University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-04-01
- Primary Topic
- Flavonoids in Medical Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00